Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $4.44
Previous CloseN/A
Volume58.77K
Average Volume (3M)503.80K
Market Cap
$275.17M
Enterprise Value$1.27B
Total Cash (Recent Filing)$99.12M
Total Debt (Recent Filing)$2.47M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Apr 01, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding129,536,120
10 Day Avg. Volume420,670
30 Day Avg. Volume503,801
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3698.00
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap4.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.65K
Enterprise Value/Ebitda-7.11
Forecast
1Y Price Target
$3.00Price Target Upside197.03% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
ProKidney News
PremiumCompany Announcements
ProKidney’s Progress in FDA Approval and Financial Health
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has $358M in cash and equivalents, which is expected to fund operations into mid-2027.
Market PotentialRilparencel is recognized for its potential in addressing the high unmet need in Type 2 diabetic Stage 3b/4 chronic kidney disease.
Regulatory ApprovalThe FDA's confirmation that a single Ph3 study could support a BLA submission and full approval is a positive step for the company.
Bears Say
Cash RunwayTopline results for the PROACT 1 study are expected beyond the company's current cash runway.
Clinical Data ConcernsNeed for more de-risking data for the product to increase Street focus and shift sentiment.
Study LimitationsThe sample size of the most recent data from the REGEN-007 study is small.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $0.86 and its highest was $4.44 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $275.17M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Apr 01, 2025 which is in 4 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Nov 12, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.012.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -0.16.
How many shares outstanding does ProKidney have?
ProKidney has 129,536,120 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in PROK
---
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (197.03% Upside)
$3.00 (197.03% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.88%
12-Months-Change
Fundamentals
Return on Equity
4.66%
Trailing 12-Months
Asset Growth
5.13%
Trailing 12-Months
Company Description
ProKidney
ProKidney (PROK) is a biotechnology company focused on the development of therapies targeting chronic kidney disease (CKD). Operating within the healthcare and biotechnology sectors, ProKidney is dedicated to pioneering innovative cellular therapies that aim to improve kidney function and provide alternative treatment options for patients with CKD. The company's core product is its proprietary Renal Autologous Cell Therapy (REACT), which is designed to harness a patient's own cells to regenerate kidney tissue and restore kidney function.
---
PROK Stock 12 Month Forecast
Average Price Target
$3.00
▲(197.03% Upside)
Technical Analysis
Fate Therapeutics
―
Rocket Pharmaceuticals
―
Crispr Therapeutics AG
―
Allakos
―
Mirum Pharmaceuticals
―
Best Analysts Covering PROK
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-50.53%
reiterated a buy rating 7 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -50.53% per trade.
---